Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Alpha Tau Medical Ltd. - Ordinary Shares (DRTS)
Company Research
Source: Yahoo! Finance
Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to -treat superficial cancers , with an overall response rate of almost 100% in treated le sions no moderate or severe long-term toxicities noted, and a 2-year local recurrence-free survival was estimated at 77% - Cash, cash equivalents & deposits balance of $ million with runway of at least two years JERUSALEM, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® reported second quarter 2024 financial results and provided a corporate update. "While we continue to advance our ReSTART U.S. multicenter pivotal trial in recurrent cutaneous squamous cell carcinoma, the overwhelming interest from clinicians and the broader community in our ongoing internal organ trials has been fantastic,” stated Alpha Tau CEO Uzi Sofer. "We are fortunate to see such strong
Show less
Read more
Impact Snapshot
Event Time:
DRTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRTS alerts
High impacting Alpha Tau Medical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
DRTS
News
- Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCCGlobeNewswire
- Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor CoGlobeNewswire
- Alpha Tau Medical Ltd. (NASDAQ: DRTS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Alpha Tau Medical Ltd. (NASDAQ: DRTS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $7.00 price target on the stock.MarketBeat
- Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
DRTS
Sec Filings
- 9/20/24 - Form 6-K
- 8/22/24 - Form 6-K
- 8/14/24 - Form 6-K
- DRTS's page on the SEC website